Printer Friendly

IMRE CORPORATION COMPLETES $2 MILLION PRIVATE OFFERING

 SEATTLE, May 3 /PRNewswire/ -- IMRE Corporation (NASDAQ: IMRE) today announced the completion of a $2 million private placement for an aggregate of 888,900 shares of the company's common stock. The proceeds will be used to further fund the company's clinical trials and research activities.
 "We are focused on obtaining additional disease indications for the Prosorba(R) column," said Frank R. Jones, Ph.D., chairman and chief executive officer of IMRE Corporation. "We are pleased to have the revenue growth due to Prosorba column sales and plan to augment the revenues with additional indications."
 The Prosorba column was approved by the FDA for commercial distribution in December 1987. It is marketed and sold for the treatment of ITP (immune thrombocytopenic purpura), an immune-related bleeding disorder. The Prosorba column treatment is based on modulation of the patient's immune system.
 IMRE Corporation, based in Seattle, is a medical products company that is a leader in the field of treating immune system diseases. The company is currently conducting clinical trials of the Prosorba column in rheumatoid arthritis and other autoimmune diseases.
 -0- 5/3/93
 /CONTACT: Lois Yoshida of IMRE Corporation, 206-298-9400; or Susan Noonan or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for IMRE Corporation/
 (IMRE)


CO: IMRE Corporation ST: Washington IN: MTC SU:

PS-LR -- NY015 -- 3594 05/03/93 09:04 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 3, 1993
Words:224
Previous Article:HOFFMAN & LAZEAR: BALLY WILL STAND TRIAL FOR AGE DISCRIMINATION
Next Article:HILTON CALLS FOR END TO 'FREQUENT TRAVEL HYPE'; URGES GUESTS TO COMPARE THE REWARDS
Topics:


Related Articles
IMRE ANNOUNCES YEAR END RESULTS
RHEUMATOID ARTHRITIS RESULTS FROM INDEPENDENT CLINICAL TRIAL OF PROSORBA COLUMN REPORTED BY IMRE CORPORATION
IMRE CORPORATION ANNOUNCES FIRST QUARTER RESULTS
RHEUMATOID ARTHRITIS RESULTS FROM INDEPENDENT CLINICAL TRIAL OF PROSORBA COLUMN SHOW LONG-TERM EFFECTS
IMRE AND BAXTER SIGN DISTRIBUTION AGREEMENT
IMRE CORPORATION ANNOUNCES FINANCING
IMRE CORPORATION ANNOUNCES YEAR-END RESULTS
IMRE SUCCESSFUL IN BAXTER RE-NEGOTIATIONS
IMRE CORPORATION ANNOUNCES SECOND QUARTER RESULTS
IMRE CORPORATION ANNOUNCES YEAR END RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters